{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rosuvastatin+40+mg+tablet", "query": { "intervention": "rosuvastatin 40 mg tablet" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T14:41:26.887Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04608344", "title": "Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Pravastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Filgotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 27, "start_date": "2020-11-04", "completion_date": "2021-01-13", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-09-26T14:41:26.887Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04608344" }, { "nct_id": "NCT03417388", "title": "Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "High dose potent statin", "type": "DRUG" }, { "name": "ACE-I (lisinopril) or ARB (losartan)", "type": "DRUG" }, { "name": "Aspirin 81 enteric coated tablet daily", "type": "DRUG" }, { "name": "Lifestyle Counseling", "type": "BEHAVIORAL" }, { "name": "Quality of Life Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 2476, "start_date": "2018-02-09", "completion_date": "2026-09-14", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-09-26T14:41:26.887Z", "location_count": 80, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03417388" }, { "nct_id": "NCT07838987", "title": "A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "TERN-701", "type": "DRUG" }, { "name": "Rabeprazole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Pravastatin", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Bosentan", "type": "DRUG" }, { "name": "Quinidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 196, "start_date": "2023-12-21", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-26T14:41:26.887Z", "location_count": 1, "location_summary": "Millcreek, Utah", "locations": [ { "city": "Millcreek", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07838987" }, { "nct_id": "NCT01489943", "title": "A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "GSK1605786 500 mg", "type": "DRUG" }, { "name": "Midazolam 3 mg", "type": "DRUG" }, { "name": "Pioglitazone 15 mg", "type": "DRUG" }, { "name": "Omeprazole 40 mg", "type": "DRUG" }, { "name": "Rosuvastatin 10 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2011-09-19", "completion_date": "2011-11-10", "has_results": false, "last_update_posted_date": "2017-07-25", "last_synced_at": "2026-09-26T14:41:26.887Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01489943" }, { "nct_id": "NCT01730053", "title": "Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2012-11-30", "completion_date": "2014-05-31", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-09-26T14:41:26.887Z", "location_count": 54, "location_summary": "Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fair Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730053" }, { "nct_id": "NCT02859129", "title": "Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypertriglyceridemia" ], "interventions": [ { "name": "rosuvastatin 40 mg tablet", "type": "DRUG" }, { "name": "Epanova™ QD (2 x 1 g capsules)", "type": "DRUG" }, { "name": "Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose", "type": "DRUG" }, { "name": "Multiple (20) oral doses of 2 g Vascepa® every 12 hours", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 114, "start_date": "2013-09", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2016-08-17", "last_synced_at": "2026-09-26T14:41:26.887Z", "location_count": 1, "location_summary": "Neptune City, New Jersey", "locations": [ { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02859129" }, { "nct_id": "NCT06948747", "title": "A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD5004", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Erythromycin", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 49, "start_date": "2025-05-06", "completion_date": "2025-10-03", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-09-26T14:41:26.887Z", "location_count": 1, "location_summary": "Brooklyn, Maryland", "locations": [ { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06948747" }, { "nct_id": "NCT01763866", "title": "LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperlipidemia" ], "interventions": [ { "name": "Evolocumab", "type": "BIOLOGICAL" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo to Evolocumab", "type": "DRUG" }, { "name": "Placebo to Ezetimibe", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 2067, "start_date": "2013-01-15", "completion_date": "2013-12-04", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-09-26T14:41:26.887Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01763866" }, { "nct_id": "NCT01730040", "title": "Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 355, "start_date": "2012-10", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-08-31", "last_synced_at": "2026-09-26T14:41:26.887Z", "location_count": 56, "location_summary": "Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730040" }, { "nct_id": "NCT01725230", "title": "Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Fostamatinib", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2012-11", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2013-02-04", "last_synced_at": "2026-09-26T14:41:26.887Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01725230" } ] }